Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Drug combination/ 26489112 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| 001 | EXPERIMENTAL | Drug combination/ 26489112 On Day 1 and on Day 19 a single oral dose of a drug combination consisting of midazolam (2 mg/mL liquid) tolbutamide (a 500 mg tablet) and omeprazole (a 20 mg capsule) will be taken and on Day 4 through Day 21 a single oral dose of two 26489112 tablets will be taken. |
| Name | Type | Description |
|---|---|---|
| Drug combination/ 26489112 | DRUG | On Day 1 and on Day 19, a single, oral dose of a drug combination consisting of midazolam (2 mg/mL liquid), tolbutamide (a 500 mg tablet), and omeprazole (a 20 mg capsule) will be taken and on Day 4 through Day 21, a single oral dose of two 26489112 tablets will be taken. |
Inclusion Criteria: * If a woman, must be postmenopausal (no spontaneous menses for at least 2 years), surgically sterile, abstinent, or, if sexually active, be practicing an effective method of birth control (e.g., intrauterine device, double-barrier method, male partner sterilization) before entr...
JNJ-26489112 is an investigational small molecule drug candidate developed by Johnson & Johnson. It has been studied in a Phase 1 pharmacokinetic and drug interaction trial in healthy adult volunteers. The specific therapeutic indication for JNJ-26489112 has not been publicly disclosed, and it remains in early clinical development.
JNJ-26489112 is being developed by Johnson & Johnson, which trades on the New York Stock Exchange under the ticker JNJ. The company sponsored the Phase 1 pharmacokinetic and drug interaction study of JNJ-26489112 conducted in healthy volunteers in Belgium.
JNJ-26489112 is in Phase 1 clinical development. It has completed one Phase 1 trial, a pharmacokinetic and drug interaction study in healthy volunteers. No later-phase trials of JNJ-26489112 have been registered, and the compound is not approved for any indication.
JNJ-26489112 has been evaluated in one registered clinical trial, NCT01147887, titled A Pharmacokinetic and Drug Interaction Study of JNJ-26489112 in Healthy Volunteers. That Phase 1 trial enrolled 20 healthy adult participants in Belgium and is completed. No active trials of JNJ-26489112 are currently listed.
The Phase 1 trial of JNJ-26489112, NCT01147887, was an uncontrolled pharmacokinetic and drug interaction study conducted in healthy volunteers. It enrolled 20 participants of all sexes, aged 18 years and older, in Belgium. The study was not randomized and not double blinded, and it is now completed.